在临床研究之外治疗500名多发性骨髓瘤患者第一次复发的治疗方法和结果
Irit Avivi1,2, Naama Yekutiel3, Tamir Shragai4,5
1Department of Hematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel. iritavi@tlvmc.gov.il.
Annals of hematology
|August 30, 2023
概括
与其他疗法相比,列纳利多米德-甲松-达拉图巴 (RD-Dara) 在多发性骨髓瘤 (MM) 患者中显著延长了第三线治疗的时间. 这项现实研究强调了RD-Dara作为MM的优质二线治疗选择.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床研究 临床研究
背景情况:
- 多发性骨髓瘤 (MM) 的治疗选择在第一次复发时正在扩大.
- 现实世界的数据对于比较新兴二线疗法的疗效至关重要.
研究的目的:
- 为了比较多发性骨髓瘤 (MM) 的常见二线治疗方案.
- 在MM患者中确定影响第三线治疗 (TT3T) 时间的因素.
主要方法:
- 来自麦卡比医疗保健服务的500名MM患者 (2014-2020年) 的回顾性分析.
- 患者在基于蛋白酶体抑制剂 (PI) 的诱导后接受了二线治疗.
- 莱纳利多米德-甲 (RD) 和莱纳利多米德-甲-达拉图 (RD-Dara) 治疗方案的比较.
主要成果:
- RD-Dara治疗与进展到第三线治疗的风险明显降低 (HR=0.5,p=0.012).
- 使用RD-Dara没有达到中位数TT3T,而使用IMID治疗方案则达到32.4个月.
- 基于蛋白质酶抑制剂 (PI) 的治疗和体重增加与更高的进展可能性有关.
结论:
- 在现实MM患者中,二线RD-Dara疗法提供了与IMID基疗法相比显著更长的TT3T.
- RD-Dara在之前接受过博特佐米布治疗的患者中显示出比PI-IMID和PI-based疗法更优异的结果.
更多相关视频
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
6.9K
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
13.1K
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Kaplan-Meier Approach
178
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
178
